Abstract
Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.
| Original language | English |
|---|---|
| Pages (from-to) | 27-34 |
| Number of pages | 8 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 24 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 1992 |
Fingerprint
Keywords
- adriamycin
- breast cancer
- chemosensitivity assay
- lonidamine
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. / Savini, Saverio; Zoli, Wainer; Nanni, Oriana; Volpi, Annalisa; Frassineti, G. Luca; Magni, Enrico; Flamigni, Alberto; Amadori, Andrea; Amadori, Dino.
In: Breast Cancer Research and Treatment, Vol. 24, No. 1, 02.1992, p. 27-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines
AU - Savini, Saverio
AU - Zoli, Wainer
AU - Nanni, Oriana
AU - Volpi, Annalisa
AU - Frassineti, G. Luca
AU - Magni, Enrico
AU - Flamigni, Alberto
AU - Amadori, Andrea
AU - Amadori, Dino
PY - 1992/2
Y1 - 1992/2
N2 - Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.
AB - Lonidamine is a new potential chemotherapeutic agent, relatively non-toxic, that can positively modulate the efficacy of several antineoplastic drugs. We evaluated the response of two established human breast cancer cell lines (MCF-7 and BRC-230) and of 20 primary breast cancer cell lines to lonidamine, either alone or in combination with adriamycin, the drug most widely used in the management of breast cancer. Different schedules were tested by varying either concentration of the drugs (LND: 10-150μg/ml; ADM: 0.10-0.15μg/ml), or time of exposure (1-96 hours), or sequence of administration (ADM → LND; LND → ADM; ADM + LND). Our results indicate slight sensitivity of the cell lines to lonidamine when used alone, whereas an increase of efficacy was noted when lonidamine was added for at least 24 hours after a 4 hour exposure to adriamycin. Such efficacy was significantly greater than that expected from an additive effect between the two drugs. We conclude that lonidamine, when given according to an appropriate schedule, enhances, in vitro, the efficacy of adriamycin. A correct employment of lonidamine in the management of breast cancer might therefore potentiate the therapeutic effect of adriamycin.
KW - adriamycin
KW - breast cancer
KW - chemosensitivity assay
KW - lonidamine
UR - http://www.scopus.com/inward/record.url?scp=0027099855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027099855&partnerID=8YFLogxK
U2 - 10.1007/BF01832355
DO - 10.1007/BF01832355
M3 - Article
C2 - 1463869
AN - SCOPUS:0027099855
VL - 24
SP - 27
EP - 34
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 1
ER -